Novo Nordisk A/S (NYSE:NVO)
| 157.14 Delayed Data As of 4:00pm ET |  -0.84 / -0.53%Today’s Change | 95.02 Today|||52-Week Range 172.97 | +16.11% Year-to-Date |
Latest NVO News | Press Releases
Today’s Trading
| Previous close | 157.98 |
| Today’s open | 155.07 |
| Day’s range | 154.44 - 157.57 |
| Volume | 1,599,713 |
| Average volume (3 months) | 1,412,476 |
| Market cap | $279.3B |
Data as of 4:00pm ET, 06/02/2023
Growth & Valuation
| Earnings growth (last year) | +4.77% |
| Earnings growth (this year) | +43.17% |
| Earnings growth (next 5 years) | +18.00% |
| Revenue growth (last year) | +11.71% |
| P/E ratio | 40.5 |
| Price/Sales | 12.30 |
| Price/Book | 30.62 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MRKMerck | +1.59 | +1.43% |
| ABBVAbbVie | +3.38 | +2.53% |
| AZNAstraZeneca | -0.25 | -0.34% |
| PFEPfizer | +0.33 | +0.87% |
Data as of 4:00pm ET, 06/02/2023
Financials
| Next reporting date | August 10, 2023 |
| EPS forecast (this quarter) | $1.28 |
| Annual revenue (last year) | $25.0B |
| Annual profit (last year) | $7.8B |
| Net profit margin | 31.38% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bagsværd, Capital Region |
Forecasts
